biostudies-literatureUnknown27(9)Boersma LVABoston Scientific<h4>Aims</h4>Clinical studies with protocol-mandated workflow and monitoring have analysed performance of pulsed field ablation (PFA) for treating atrial fibrillation (AF). The FARADISE registry captures global use of the pentaspline PFA catheter in real-world clinical practice with a follow-up of 3 years.<h4>Methods and results</h4>FARADISE is a prospective, non-randomized, multi-national registry (NCT05501873) that enrolled subjects clinically indicated for ablation using the pentaspline PFA catheter per medical judgement and hospital standard-of-care. Procedural characteristics, safety, and clinical effectiveness up to 12-months were collected. In total, 1158 AF patients received PFA across 48 centres in 21 countries (64 ± 11 years, 33% female, 90% de novo, 65% paroxysmal AF). PulmonaryEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiologyeuaf182https://www.ebi.ac.uk/biostudies/studies/S-EPMC12400809biostudies-literatureReal-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry.PMC12400809Willems SSolimene FHussin AJohnson MGarcia-Bolao ILugenbiel PCielen NSzegedi NAlbrecht EMDefaye POsca JSutton BSHerzet JMBoersma LVAHaqqani HDello Russo AEckardt LFiala MAbbey SAndrikopoulos GOuss AVijgen JMaqueda JREfremidis MSzeplaki GLuik AGandjbakhch EfalseReal-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry.<h4>Aims</h4>Clinical studies with protocol-mandated workflow and monitoring have analysed performance of pulsed field ablation (PFA) for treating atrial fibrillation (AF). The FARADISE registry captures global use of the pentaspline PFA catheter in real-world clinical practice with a follow-up of 3 years.<h4>Methods and results</h4>FARADISE is a prospective, non-randomized, multi-national registry (NCT05501873) that enrolled subjects clinically indicated for ablation using the pentaspline PFA catheter per medical judgement and hospital standard-of-care. Procedural characteristics, safety, and clinical effectiveness up to 12-months were collected. In total, 1158 AF patients received PFA across 48 centres in 21 countries (64 ± 11 years, 33% female, 90% de novo, 65% paroxysmal AF). Pulmonary2025-01-01T00:00:00Z2025 Sep2026-06-03T10:15:29.193Z2026-04-26T03:12:02.636ZS-EPMC124008094088873510.1093/europace/euaf182